{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:13:25Z","timestamp":1772244805098,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01588-8","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T18:14:12Z","timestamp":1762798452000},"page":"653-658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Evidence on Dose Spacing of Risankizumab for Psoriasis: A Multicenter Retrospective Cohort Study"],"prefix":"10.1007","volume":"16","author":[{"given":"Martim","family":"Luz","sequence":"first","affiliation":[]},{"given":"Ana Lu\u00edsa","family":"Jo\u00e3o","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Mendes-Bastos","sequence":"additional","affiliation":[]},{"given":"\u00c2ngela","family":"Roda","sequence":"additional","affiliation":[]},{"given":"Luiz","family":"Leite","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Val\u00e9rio","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Ferreirinha","sequence":"additional","affiliation":[]},{"given":"Barbara","family":"Leal","sequence":"additional","affiliation":[]},{"given":"Maria Jo\u00e3o","family":"Paiva Lopes","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Pimenta","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Ferreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"2","key":"1588_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s13555-025-01342-0","volume":"15","author":"D Thaci","year":"2025","unstructured":"Thaci D, Ohtsuki M, Maul JT, Szegedi A, Luna PC, Lynde CW, et\u00a0al. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis: interim analysis from the VALUE global prospective post-marketing observational study at 25 months. Dermatol Ther (Heidelb). 2025;15(2):381\u201394. https:\/\/doi.org\/10.1007\/s13555-025-01342-0.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1588_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00951-x","author":"T Torres","year":"2025","unstructured":"Torres T, Joao AL, Luz M, Mendes-Bastos P, Roda A, Leite L, et\u00a0al. Real-world effectiveness, safety, and drug survival of risankizumab in adult patients with plaque psoriasis: a 3-year multicenter retrospective cohort study. Am J Clin Dermatol. 2025. https:\/\/doi.org\/10.1007\/s40257-025-00951-x.","journal-title":"Am J Clin Dermatol"},{"key":"1588_CR3","doi-asserted-by":"publisher","first-page":"1331217","DOI":"10.3389\/fimmu.2024.1331217","volume":"15","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Eyerich K, Kuchroo VK, Ritchlin CT, Abreu MT, Elloso MM, et\u00a0al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217. https:\/\/doi.org\/10.3389\/fimmu.2024.1331217.","journal-title":"Front Immunol"},{"issue":"9","key":"1588_CR4","doi-asserted-by":"publisher","first-page":"e713","DOI":"10.1111\/jdv.18182","volume":"36","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Maurelli M, Bellinato F, Girolomoni G. Is risankizumab as needed administration a good option for patients with plaque psoriasis? J Eur Acad Dermatol Venereol. 2022;36(9):e713\u20135. https:\/\/doi.org\/10.1111\/jdv.18182.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1588_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70062","volume":"34","author":"L Mastorino","year":"2025","unstructured":"Mastorino L, Dapavo P, Ortoncelli M, Bongiovanni E, Liao Y, Leo F, et\u00a0al. Dose modulation strategies in psoriatic patients: real-life pilot comparison between Risankizumab and Guselkumab up to 12 months after dose spacing. Exp Dermatol. 2025;34(2):e70062. https:\/\/doi.org\/10.1111\/exd.70062.","journal-title":"Exp Dermatol"},{"issue":"7","key":"1588_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40261-023-01280-9","volume":"43","author":"P Herranz-Pinto","year":"2023","unstructured":"Herranz-Pinto P, Alonso-Pacheco ML, Feltes-Ochoa R, Mayor-Ibarguren A, Servera-Negre G, Busto-Leis JM, et\u00a0al. Real-world performance of a new strategy for off-label use of guselkumab in moderate to severe psoriasis: super-responder patients as the epitome of efficacy and optimisation. Clin Drug Investig. 2023;43(7):517\u201327. https:\/\/doi.org\/10.1007\/s40261-023-01280-9.","journal-title":"Clin Drug Investig"},{"issue":"10","key":"1588_CR7","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s13555-024-01258-1","volume":"14","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Blauvelt A, Sima AP, Beaty SW, Low R, Gomez B, et\u00a0al. Impact of disease factors of patients with psoriasis and psoriatic arthritis on biologic therapy switching: real-world evidence from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2024;14(10):2805\u201325. https:\/\/doi.org\/10.1007\/s13555-024-01258-1.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1588_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/ijd.16917","volume":"63","author":"G Caldarola","year":"2024","unstructured":"Caldarola G, Falco GM, Calabrese L, D\u2019Amore A, Chiricozzi A, Mariani M, et\u00a0al. Drug survival of biologics and non-biologics in patients affected by palmoplantar psoriasis: a \u201creal-world,\u201d mono-center experience. Int J Dermatol. 2024;63(1):51\u20138. https:\/\/doi.org\/10.1111\/ijd.16917.","journal-title":"Int J Dermatol"},{"issue":"10","key":"1588_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","volume":"41","author":"F Pirro","year":"2021","unstructured":"Pirro F, Caldarola G, Chiricozzi A, Burlando M, Mariani M, Parodi A, et\u00a0al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917\u201325. https:\/\/doi.org\/10.1007\/s40261-021-01080-z.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"1588_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/14712598.2023.2244872","volume":"23","author":"S Ribero","year":"2023","unstructured":"Ribero S, Ortoncelli M, Mastorino L, Quaglino P, Dapavo P. Reduced doses of biological therapies in psoriasis: a new potentially \u201csustainable\u201d frontier of psoriasis treatment. Expert Opin Biol Ther. 2023;23(9):867\u20138. https:\/\/doi.org\/10.1080\/14712598.2023.2244872.","journal-title":"Expert Opin Biol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01588-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01588-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01588-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:19Z","timestamp":1770190819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01588-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1588"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01588-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Apogee Therapeutics, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Johnson & Johnson Innovative Medicine, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, STADA, and UCB. Tiago Torres is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Ana Lu\u00edsa Jo\u00e3o has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by Abbvie, Almirall, Janssen, Leo Pharma, Merck, Novartis, and Sanofi. Pedro Mendes-Bastos has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Almirall, Alumis, Amgen, Apogee, Biogen, CS Labs, Eli-Lilly, Evelo Biosciences, Janssen-Cilag, Leo-Pharma, L\u2019Oreal, Novartis, Organon, Pfizer, Pierre Fabre, Regeneron, Sanofi, and Viatris. \u00c2ngela Roda has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by Abbvie, Almirall, Janssen, and Novartis. Maria Jo\u00e3o Paiva Lopes has participated in clinical trials, advisory boards, and\/or lectures promoted by AbbVie, Almirall, Boehringer Ingelheim, Janssen, Leo-Pharma, Eli Lilly, Novartis, Pfizer, Sanofi-Genzyme, and Viatris. Rita Pimenta has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by Abbvie, Almirall, Janssen, and LEO Pharma. Paulo Ferreira has received consultancy and\/or speaker\u2019s honoraria from Abbvie, Almirall, Janssen, LEO Pharma, Lilly, and Novartis. Martim Luz, Luiz Leite, Joana Val\u00e9rio, Ana Ferreirinha, and Barbara Leal have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}